Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

-Data also presented today at European Society of Cardiology Congress

2007--

PALO ALTO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna, Austria shows that Ranexa(R) (ranolazine extended-release tablets) reduced both ventricular and atrial arrhythmias in patients receiving Ranexa compared to placebo in the MERLIN TIMI-36 study.

Patients receiving Ranexa had a 37 percent reduction in their relative risk of ventricular tachycardia lasting eight beats or more (p<0.001) and there were fewer episodes of sudden cardiac death observed in patients taking ranolazine (56) than in patients taking placebo (65).

As part of the MERLIN TIMI-36 safety assessment, Holter monitors recorded continuous ECG recordings for the first seven days after patients were admitted to the study with an episode of non-ST elevation myocardial infarction or unstable angina. Patients are typically especially susceptible to arrhythmic events during the first seven days following a heart attack. The more than 1,000,000 hours of Holter monitor data from 6,351 study participants are believed to represent the largest Holter monitor database ever collected in a clinical trial.

"The significant reductions in ventricular arrhythmias observed in ranolazine patients in the MERLIN TIMI-36 study provide important and reassuring data regarding the long-term safety of ranolazine and suggest that ranolazine could have potential as a new anti-arrhythmic agent in treating ventricular arrhythmias," said Benjamin Scirica, a cardiologist at Brigham and Women
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... a significant percentage of Americans, the answer is no, ... the science of the very small. , Addressing scientists ... of the American Association for the Advancement of Science, ... sciences communication, presented new survey results that show religion ...
... that Significantly Raises HDL "Good" Cholesterol and Lowers ... ... ABBOTT PARK, Ill., Feb. 15 Today, Abbott,received U.S. Food and ... widely prescribed cholesterol,therapies, Niaspan(R) (Abbott,s proprietary niacin extended-release) and,simvastatin. SIMCOR is ...
... Pharma (Oxford, UK), a,Vaccinex collaboration partner, has announced ... discovered by Vaccinex, to,GlaxoSmithKline., According to the ... an up-front,license fee, development milestones, and royalties on ... develop and commercialize,OP-R003 for the treatment of rheumatoid ...
Cached Biology Technology:Religion colors Americans' views of nanotechnology 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 4Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 5Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 6Vaccinex Antibody Licensed to GlaxoSmithKline 2
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):
... factor only just beginning to be appreciated by social ... Terje Tvedt, of the Universities of Oslo and Bergen, ... role in shaping societies throughout human history. Speaking at ... in October, Tvedt proposed that social scientists and historians ...
... vice president for technology development at NJIT, has been ... and Technology to assist faculty researchers with the most ... $50,000. The money, known as Gap grants, is ... idea and a commercial product. Sixteen grants ...
... Carolina at Chapel Hill researchers using brain imaging of ... that may mark the onset of autistic symptoms is ... in funding. , The Infant Brain Imaging Study ... awarded $10 million in 2007 by the National Institutes ...
Cached Biology News:Using water to understand human society, from the industrial revolution to global trade 2Using water to understand human society, from the industrial revolution to global trade 3Moving new technologies from the lab to the marketplace 2Moving new technologies from the lab to the marketplace 3UNC expands brain imaging study of infants at risk for autism 2
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Cyno macaque plasma and serum - various quantities available...
Biology Products: